<DOC>
	<DOC>NCT01464411</DOC>
	<brief_summary>The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.</brief_summary>
	<brief_title>Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Newly diagnosed Chronic Myeloid Leukemia in the Chronic Phase 20 years old over ECOG performance status (PS) score 02 Adequate organ function (hepatic, renal and lung) Signed written informed consent A case with the double cancer of the activity Women who are pregnant or breastfeeding The case of Pleural effusion clearly Patients with complications or a history of severe or uncontrolled cardiovascular failure following have a Myocardial infarction whithin 6 months have an Angina within 3 months have a Congestive heart failure within 3 months have a QTc interval of more than 450msec at baseline A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>chronic phase</keyword>
	<keyword>Phase II</keyword>
	<keyword>dasatinib</keyword>
</DOC>